Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESAGE: Ovarian stimulation with tamoxifen for fertility preservation prior to chemotherapy in breast cancer
2024-516282-37-00Phase 2Authorised
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Aug 2024
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of follitropin beta, tamoxifen, cetrorelix and recombinant human chorionic gonadotrophin in breast cancer, sponsored by Institut Cancérologique de l'Ouest. Primary endpoint: Feasibility of ovarian stimulation. Planned start Aug 2024; status: authorised.
02
Drugs
follitropin betatamoxifencetrorelixrecombinant human chorionic gonadotrophin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516282-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516282-37-00.